Vantive, a planned spin-off from U.S.-based Baxter International (NYSE: BAX) specializing in kidney care, has entered into separate collaboration agreements with the Chinese unit of UK’s Kertone Ltd. and Hangzhou Qiantang Longyue Biotechnology Co., Ltd. at the 7th China International Import Expo (CIIE). These partnerships focus on hemodialysis and peritoneal dialysis, respectively.
Enhancing Hemodialysis Water Treatment and Patient Experience
Hemodialysis, the most prevalent treatment method in renal replacement therapy, is vital for end-stage renal disease patients. Water machines are crucial for ensuring the purity of treatment water and the safety of dialysis. The collaboration between Vantive and Kertone will leverage Kertone’s expertise in smart water treatment to provide more reliable dialysis water for hemodialysis patients. The integration of an AI intelligent remote management system will enhance the customer operation experience and improve the quality of dialysis for patients.
Advancing Peritoneal Dialysis Solutions with Qiantang Longyue
Peritoneal dialysis is a critical renal replacement therapy for patients with end-stage kidney disease, making the peritoneal dialysis catheter essential for treatment. The partnership between Vantive and Qiantang Longyue will draw on Qiantang Longyue’s experience in polymer drug infusion devices and precision medical devices to develop peritoneal dialysis pathway solutions tailored to the Chinese market. This collaboration aims to advance peritoneal dialysis catheterization technology, enabling more end-stage renal disease patients to benefit from peritoneal dialysis therapy.
Carlyle’s Acquisition of Vantive from Baxter International
In related news, Carlyle agreed to acquire Vantive from Baxter in August 2024, with the deal expected to close in late 2024 or early 2025.- Flcube.com
